Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.
Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.
Thyme Care: A Human Touch in Cancer Care, Guided by Technology
June 23rd 2022Oncologist and health tech veteran Bobby Green, MD, who practiced for 17 years in Florida and was previously with Flatiron, is now Thyme Care’s president and chief medical officer. He has relocated to Nashville, Tennessee, to launch Thyme Care.
Read More
Bringing Innovation to Value-Based Care at Scale, With an Assist From Technology
June 23rd 2022The Institute of Value-Based Medicine® (IVBM), hosted by Tennessee Oncology, brought health care leaders together on April 21 in Nashville, Tennessee, to discuss oncology care delivery—and to see colleagues in person, some for the first time since 2020.
Read More
COTA’s Miruna Sasu on Real-world Evidence: “The Ecosystem Has Changed”
June 23rd 2022Miruna Sasu, PhD, MBA, became president and CEO of COTA Healthcare in March 2022, not quite a year after joining the company as its chief strategy officer. As the importance of RWD grows, Sasu is ready to take its use in precision oncology to new levels. She spoke with Evidence-Based Oncology™ (EBO) about her new role.
Read More
Florida Cancer Specialists’ Walcker: Taking a “Holistic” Approach to Value-Based Care
June 23rd 2022Nathan H. Walcker, MBA, CEO of Florida Cancer Specialists & Research Institute (FCS) since August 2020, discusses the future of value-based care for the practice as the Oncology Care Model comes to an end.
Read More
Women “Significantly” More Likely to Develop Long COVID, Review Finds
June 22nd 2022The study, published in Current Medical Research and Opinion, finds that females were 22% more likely than males to have long COVID, which was defined as having symptoms that lasted more than 4 weeks after onset.
Read More
Dr Debra Patt: Telemedicine’s Contribution to Cancer Care Robust and Meaningful
June 20th 2022Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, discusses how enhancements to telemedicine precipitated by the COVID-19 pandemic have made lasting and meaningful changes to oncology care, including that these care improvements will persist post pandemic.
Read More
Challenging the “One-Size-Fits-All” Approach in Early MCL Treatment
June 19th 2022Anita Kumar, MD, medical oncologist with Memorial Sloan Kettering Cancer Center, led a session at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO), on New Directions in Mantle Cell Lymphoma.
Read More
Dr Hope S. Rugo Discusses Clinical Trial Minority Recruitment, PALOMA-2 Findings
June 16th 2022Hope S. Rugo, MD, FASCO, is professor of medicine and the director of the Breast Oncology and Clinical Trials Education program at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center. She discusses her experience with palbociclib and letrozole in advanced breast cancer.
Read More
Banner|Aetna Puts More Decisions, and Risk, in Hands of Providers
June 10th 2022In a panel discussion, “Banner|Aetna: Collaboration as a Business Imperative,” part of the Matters in Managed Care webinar series, panelists discussed how payers and providers can work as partners to deliver care with aligned financial interests.
Read More
Inovio's DNA Vaccine Combo Plus Cemiplimab Shows Promise in Glioblastoma
June 7th 2022The results involve a pair of DNA medicines combined with cemiplimab, which is approved as Libtayo to treat other solid tumors. In this study, the regimen is designed to prime a T-cell response before a patient receives radiation.
Read More
Dr Kim A. Reiss: There Are Several Exciting Developments in Pancreatic Cancer Research
June 6th 2022Kim A. Reiss, MD, assistant program director of the Hematology/Oncology Fellowship Program and assistant professor of medicine at the Hospital of the University of Pennsylvania, discusses pancreatic cancer research she presented at the 2022 American Society of Clinical Oncology Annual Meeting.
Read More
Dr Joel W. Neal: Cabozantinib/Atezolizumab May Fullfill Unmet Targeted Treatment Need in NSCLC
June 6th 2022Joel W. Neal, MD, PhD, associate professor, Division of Oncology, Stanford Cancer Institute, is lead investigator on the COSMIC-021 trial, which is investigating cabozantinib plus atezolizumab vs cabozantinib alone in patients with advanced non–small cell lung cancer (NSCLC) as a possible second-line treatment beyond chemotherapy.
Read More
ASCT Early in Multiple Myeloma Treatment Improves PFS, but OS Same as RVd
June 6th 2022Results presented at the American Society of Clinical Oncology Annual Meeting showed a 21.4-month advantage for autologous stem cell transplant (ASCT) over a common triplet therapy in progression-free survival (PFS) but no advantage in overall survival (OS).
Read More
Practice-changing data from the DESTINY-Breast04 study, presented during the 2022 Annual Meeting of the American Society of Clinical Oncology in Chicago, show that trastuzumab deruxtecan reduced the risk of disease progression or death by 50% compared with chemotherapy for human epidermal growth factor receptor-2 (HER2)–low patients with both hormone receptor (HR)–positive and HR-negative disease.
Read More
Dr David R. Penberthy: Knowledge Gained at ASCO Can Transform Cancer Care
June 5th 2022David R. Penberthy, MD, MBA, is medical director, Radiation Oncology, Bon Secours-Southside Medical Center in Petersburg, Virginia, and president of the Association of Community Cancer Centers for the 2022-2023 term.
Read More
Dr Kashyap Patel Discusses the Importance of WES in Reducing Targeted Treatment Disparities
June 4th 2022Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates, current president of the Community Oncology Alliance, and associate editor of Evidence-Based Oncology™, discusses his partnership with Sema4 and LabCorp and their joint goal to advance whole-exome sequencing (WES) for targeted oncology treatment.
Read More
Dr Enrique Ocio Discusses the Advantages of Sub-Q Isatuximab for RRMM
June 4th 2022Enrique Ocio, MD, PhD, hematology department head, Marqués de Valdecilla University Hospital, Santander, Spain, discusses phase 1b trial results for subcutaneous (sub-Q) vs intravenous isatuximab, both formulations administered in combination with pomalidomide and dexamethasone for relapsed/refractory multiple myeloma (RRMM).
Read More
ASCO, WHO to Launch Global Quality Initiative in Cancer Care
June 4th 2022The collaboration, put in place through a Memorandum of Understanding, was presented Saturday in a keynote address by WHO Cancer Control Officer André Ilbawi, MD, during the presidential symposium at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago.
Read More
Over 6 Years, First-line Brentuximab Vedotin Cuts Risk of Death in Hodgkin Lymphoma by 41%
June 4th 2022Data presented at ASCO show that after 6 years, patients with advanced Hodgkin lymphoma who were treated with a combination of brentuximab vedotin and chemotherapy had a sharply reduced risk of death and a reduced risk of a secondary cancer.
Read More
ASCO Returns to Chicago, With Health Equity and Innovation on the Agenda
June 2nd 2022For the second year, the meeting will focus on health equity, as American Society of Clinical Oncology (ASCO) President Everett Vokes, MD, FASCO, has selected the theme “Advancing Equitable Cancer Care Through Innovation.”
Read More
Dr Randall A. Oyer: Clinical Trials Must Be Accessible to Everyone
June 1st 2022Randall A. Oyer, MD, medical director, oncology, and medical director, Cancer Risk Evaluation Program, Lancaster General Health, and clinical professor of cancer biology at Penn Medicine, discusses the recent American Society of Clinical Oncology/Association of Community Cancer Centers recommendations for improving diversity in clinical trials.
Read More
Dr Kashyap Patel Updates on Exciting Developments at ASCO22
June 1st 2022Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates, current president of the Community Oncology Alliance, and associate editor of Evidence-Based Oncology™, talks with us ahead of the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Read More
Nivolumab-Based Combos Approved in First-line Advanced ESCC
May 28th 2022The approvals were announced by Bristol Myers Squibb (BMS), maker of the 2 immunotherapy treatments approved for 1 combination: nivolumab (Opdivo), the first approved PD-1 immune checkpoint inhibitor, and ipilimumab (Yervoy), which activates the immune system by targeting CTLA-4.
Read More
Increased Social Spending by States Linked to Improved OS for Black Patients With Cancer
May 26th 2022Data to be presented next week during the American Society of Clinical Oncology Annual Meeting show that for every 10% increase in public welfare spending, there was a 4.55% narrowing of the 5-year overall survival (OS) disparity between Black and White patients with cancer.
Read More